Conflicts of Interest in Psychedelic Research and Treatment

A post on conflicts of interest in academic research, personal interests of scientists and the motivation to build a private company.

German Authorities Approve Psilocybin Depression Study

The German Federal Institute for Drugs and Medical Devices (BfArM) approved our study on “Efficacy and Safety of Psilocybin in Treatment-Resistant Depression” (EPIsoDE).

German Government Funds Psilocybin Study for Depression

Our study with psylocin in depression was recommended for funding from the German Federal Ministry of Education and Research.

Psychedelics in German Television

A TV broadcast in the German WDR on the renaissance of psychedelics, especially on the use of LSD “microdosing”, but also on their therapeutical potential.

A Lecture on News in Psychopharmacology

My lecture on “Hot Topic: Psychopharmaka”, held in Mainz on March 15th, 2019, as part of the teaching event “Psychiatrie Update 2019”, was videotaped.

Interviews on Esketamine, Depression and the Wish to have Children

A brief post on some interviews I gave recently on esketamine for treatment-resistant depression and depression in women who have problems getting pregnant.

FDA Approves Esketamine for Treatment-Resistant Depression, While US Suicide Rate Reaches Record High

The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.

Esketamine for treatment-resistant depression submitted to FDA

Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.

How Common are Withdrawal and Emotional Blunting in Chronic Antidepressant Treatment?

The problem of withdrawal syndromes and emotional blunting occurring with prolonged antidepressant treatment is constantly underestimated by clinicians.

The Antidepressant Debate in the New York Times

An article on the front page of the New York Times on April 7, 2018, has fueled the debate over antidepressants again.